Abstract
Background The SARS-CoV-2 epidemic in Mexico is growing, and there is uncertainty regarding the role that different age groups play in propagating the epidemic.
Methods We used data on hospitalizations with confirmed SARS-CoV-2 infection from the Mexican Ministry of Health in ten 5-year age groups: 10-14through 55-59 years. For each age group g, we computed the proportion E(g) of individuals in that age group among all hospitalized cases aged 10-59 years during the early period (between April 20 – May 3, 2020), the corresponding proportion L(g) during the later periods (May 11-24), as well as the relative risk RR(g)= L(g)/E(g). For each pair of age groups g1,g2, RR(g1)>RR(g2) is interpreted as a relative increase in SARS-CoV-2 infections in the age group g1 compared with g2 for the later vs. early period.
Results The highest RR estimates belong to persons aged 15-19 years (RR=1.93(95% CI (1.19,3.12)) and 20-24 years (RR=1.40(1.07,1.83)). The RR estimates in persons aged over 30 years were significantly lower compared to persons aged 15-24 years.
Conclusions Our results suggest a temporal increase in the incidence of SARS-CoV-2 infection in older adolescents and younger adults compared to other age groups. Targeted interventions, particularly public health messaging at those age groups to increase knowledge and risk awareness may be considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used deidentified publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used public data from Mexico's Ministry of Health